RossMichaelTonkensMD

PubMed

• 67 citations
  First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention
  Mauricio G. Cohen, Drew A. Purdy, Joseph S. Rossi, Liliana Grinfeld, Shelley K. Myles
  Circulation. 2010-08-10
• 105 citations
  Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease
  Mark Y. Chan, Mauricio G. Cohen, Christopher K. Dyke, Shelley K. Myles, Laura G. Aberle
  Circulation. 2008-06-03
• 78 citations
  A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor
  Mark Y. Chan, Christopher P. Rusconi, John H. Alexander, Ross M. Tonkens, Robert A. Harrington
  Journal of Thrombosis and Haemostasis. 2008-05-01

Journal Articles

• The Arguments for Maintaining Professional Licensure While Working in Industry.  
  Huml, R., Tonkens, R, Regulatory Focus, pp. 48-50
• CMC, Preclinical and Clinical Considerations for Biosimilars and Follow-on Biologics.  
  Huml, R., Hicks, P., Chance, K., Howe, K., Tonkens, R, Regulatory Affairs Focus, pp. 20-27
• Follow-on Biologics in the EU & US.  
  Huml, R., Chance, K., Howe, K., Hicks, P., Tonkens, R, Regulatory Affairs Focus, pp. 8-13
• Partnering Alternatives for Biotechnology Companies.  
  Huml, R., Bullard, M., Tonkens, R, Regulatory Affairs Focus, pp. 34-37
• An Introduction to Alliance Management.  
  Mazzetti, R., Huml, R., Tonkens, R, Regulatory Affairs Focus, pp.43-46
• An Overview of Research and Development Due Diligence.  
  Huml, R., Tonkens, R., Tunnicliffe, J, Regulatory Affairs Focus, pp. 24-28
• An Update on the Implications of QT Interval Prolongation.  
  Huml, R., Tonkens, R., Barker, G., Herbert, D, Regulatory Affairs Focus, pp. 37 - 41
• Transitioning from Private Practice to Industry.  
  Huml, R, Barker, G., Tonkens, R, Veterinary Forum, pp. 52 - 55
• The Clinical and Regulatory Implications of QT Interval Prolongation.  
  Huml, R., Barker, G., Tonkens, R., Herbert, D, Regulatory Affairs Focus, 9:40-43
• Guided tour’ of UCSD Pascal Units and Libraries.  
  Tonkens, R, BYTE, 7:225-244
• Animated Color Graphics in UCSD Pascal.  
  Tonkens, R, Creative Computing, 8:98-108
• Detection of Induced Segmental Abnormalities Using Two Dimensional Echocardiography.  
  Effron, H., Tonkens, R., Beeder, C, Circulation, 62:III-185
• Hand Held Programmable Computers in Emergency and Critical Care.  
  Tonkens, R., Brill, J, JACEP, 8:116- 117
• Elemental Diet and Bile Induced Pancreatitis.  
  Kerstein, M., and Tonkens, R, Surgery, Gynecology, & Obstetrics, 143:253-256
• Join now to see all

Books/Book Chapters

• Pharmaceutical Competitive Intelligence for the Regulatory Affairs Professional. 
  Huml, R., Tonkens, R.-ForewardSpringer Sciences+Business Media, New York
• Introduction to the Due Diligence Process. 
  Huml, R., Tonkens, REditors: Tonkens, R.Springer Sciences+Business Media, New York
• Creative Computing Software Guide. 
  Chapter: UCSD Pascal 1.1: A User's Evaluation 
  Tonkens, RAhl Computing, Inc, Morris Plains, NJ

Abstracts/Posters

• Developing Novel Anticoagulants.
  Tonkens, Ross M, Conducting Cardiovascular Research in Emerging Countries in a Challenging Economic Environment, Prague, Czech Republic
• Creative Funding Options for Biotechs in Challenging Economic Times.
  Tonkens, Ross M, Conducting Cardiovascular Research in Emerging Countries in a Challenging Economic Environment, Prague, Czech Republic
• Factor IXa Inhibition with REG1 Provides Rapid Onset, Stable and Actively Controlled Anticoagulation during PCI.
  Cohen, Mauricio, G., Purdy, Drew A., Rossi, Joseph S., Grinfeld, Liliana, Myles, Shelley K., Aberle, Laura H., Greenbaum, Adam B., Fry, Edward, Chan, Mark Y., Zelenkof..., American College of Cardiology Annual Scientific Session
• A First-in-Class Oligonucleotide Drug-Antidote Pair Efficiently Modulates Factor IXa Activity in Human Subjects - A Nascent Platform for Antidote-Controlled Periproced...
  Chan, M Y, Cohen, M G, Rusconi, C P, Alexander, J H, Tonkens, R M, Harrington, R C, Becker, R C, et al, American Heart Association Annual Scientific Session
• Antidote-Controlled Modulation of Factor IXa Activity with the First-in-Class REG1Anticoagulation System: A Randomized Phase 1 Repeat Dose Safety and Antidote Dose-Esc...
  Chan, M Y, Cohen, M G, Rusconi, C P, Tonkens R M, Harrington, R C, Becker, R C, American Heart Association Annual Scientific Session
• Abstract 1555: Antidote-Controlled Modulation of Factor IXa Activity with the First-in- Class REG1 Anticoagulation System: A Randomized Phase 1 Repeat Dose S...
  Chan, Mark Y., Alexander, John H., Rusconi, Christopher P., Tonkens, Ross M., Harrington, Robert A., Becker, Richard C, Circulation; 116:II_323
• Abstract 2780: A First-in-Class Oligonucleotide Drug-Antidote Pair Efficiently Modulates Factor IXa Activity in Human Subjects - A Nascent Platform for Antidote-Contro...
  Chan, Mark Y., Cohen, Mauricio G., Rusconi, Christopher P., Alexander, John H., Myles, Shelley K., Aberle, Laura G., Lin, Min, Melloni, Chiara., Tonkens, Ross M., Har..., Circulation; 116:II_617-b
• Principles of Cardiovascular Disease, Therapeutics, and Clinical Trial Oversight.
  Tonkens, R, Teaching Program for Quintiles Global University, Multiple Locations, 2004, 2005
• Per Cent Systolic Area Change: A Method of Quantifying Regional Wall Motion Abnormalities by Two Dimensional Echo.
  Tonkens, R., Effron, H., Loh, I., Beeder, C, American Heart Association Annual Scientific Session, Miami Beach
• Join now to see all

Other

• Careers in Pharmaceutical Medicine. 
  Tonkens, R, Web Lecture
  http://www.acpe.org/toolkit/
  American College of Physician Executives